Medically reviewed by a board-certified nuclear medicine physician and oncology specialist. Last reviewed: June 2026.

Lu-177 PSMA After Docetaxel: mCRPC Eligibility Guide

This article is for patients on the PSMA track - men with metastatic castration-resistant prostate cancer (mCRPC). If your doctor has told you that docetaxel chemotherapy is no longer working, you may be wondering what comes next. Lu-177 PSMA therapy may be an option. For many men in your situation, it is a next step backed by solid research.

Lutetium Lu-177 vipivotide tetraxetan - sold under the brand name Pluvicto - is a type of radioligand therapy (RLT). The FDA approved it in March 2022 for men with PSMA-positive mCRPC who had already received both a hormone therapy drug and taxane-based chemotherapy - which includes docetaxel. This means the research focused on patients like you.

What Happens to mCRPC When Docetaxel Stops Working?

Metastatic castration-resistant prostate cancer is a stage of disease where cancer keeps growing even though hormonal treatments keep testosterone levels very low. Docetaxel - given by IV infusion every three weeks - is one of the main chemotherapy drugs used at this stage. It can slow the disease for some time, but most prostate cancers eventually stop responding.

When docetaxel stops working, several treatment paths may be considered. Cabazitaxel is another chemotherapy drug that may help some men. Hormone therapy drugs called androgen receptor pathway inhibitors (ARPIs) - such as enzalutamide or abiraterone - may still help if you haven't already tried them. And for men whose cancer carries a protein called PSMA on its surface in sufficient amounts, radioligand therapy is now an option supported by a large trial.

The right path depends on your specific treatment history, what your cancer cells look like on imaging, and how your body is doing overall. No single option fits every patient at this point.

What Is Lu-177 PSMA Therapy and How Does It Work?

Lu-177 PSMA therapy is a form of radioligand therapy. Think of it as a guided delivery system. A small molecule called a ligand finds and binds to PSMA - prostate-specific membrane antigen - a protein found on the surface of most prostate cancer cells. Once it binds, the radioactive lutetium-177 it carries releases a targeted dose of radiation directly to the cancer cell and nearby cells.

This belongs to a field called theranostics. The same PSMA target used to find cancer on a PET scan is used to treat it. The protein that lit up on your PSMA PET scan is the target this therapy binds to and destroys. Healthy surrounding tissue absorbs much less radiation than tumor cells - though some nearby tissues, particularly the salivary glands and kidneys, do receive some radiation.

The drug's full international name is lutetium Lu-177 vipivotide tetraxetan. Its brand name is Pluvicto. Both names are useful when speaking with a specialist or reviewing your options across different countries.

What Does the Evidence Show About Lu-177 PSMA After Chemotherapy?

The main evidence comes from the VISION trial - a large, international, randomized trial. It enrolled men with progressive PSMA-positive mCRPC who had already received at least one ARPI (a hormone therapy drug such as enzalutamide or abiraterone) and one to two prior taxane-based chemotherapy regimens, which could include docetaxel.

The VISION trial results showed that men who received lutetium Lu-177 vipivotide tetraxetan along with best standard of care lived a median of 15.3 months. Men who received best standard of care alone lived a median of 11.3 months. The hazard ratio for overall survival was 0.62, meaning the risk of death dropped by about 38 percent during the study. The trial also showed that disease progression slowed.

Here is a quick summary of what the VISION trial required before treatment - this also serves as an eligibility checklist:

• At least one PSMA-positive lesion on PSMA PET/CT imaging, with tracer uptake visually greater than liver background
• No PSMA-negative measurable metastatic lesion - all measurable lesions must show PSMA expression
• Prior treatment with at least one androgen receptor pathway inhibitor (ARPI)
• Prior treatment with one to two taxane-based chemotherapy regimens (docetaxel and/or cabazitaxel)
• Adequate kidney, liver, and bone marrow function confirmed by blood tests
• ECOG performance status of 0 to 2

A separate trial called TheraP, conducted in Australia, enrolled men with mCRPC whose cancer had progressed on docetaxel. TheraP compared Lu-177 PSMA therapy directly against cabazitaxel chemotherapy. Results presented at ASCO showed that more men on Lu-177 PSMA therapy had a PSA response, and fewer men experienced severe side effects compared to those on cabazitaxel. This gives direct evidence that Lu-177 PSMA may offer benefit in the post-docetaxel setting - not just in a general mCRPC population.

Who Qualifies for Lu-177 PSMA After Docetaxel - The Key Criteria

To be considered for lutetium Lu-177 vipivotide tetraxetan, your care team will review several criteria. Here is what each one means in practice:

PSMA-positive disease on PET scan. This is the single most important eligibility gate. You need a PSMA PET/CT scan - typically using a tracer called gallium-68 PSMA-11. According to the FDA clinical review of lutetium Lu-177 vipivotide tetraxetan, the VISION trial required tracer uptake in lesions to be visually greater than the signal seen in the liver. Additionally, there must be no measurable metastatic lesions that are PSMA-negative - a mixed picture can affect eligibility. About 12 to 13 percent of men screened for VISION did not pass this imaging step.

Prior ARPI treatment. You must have already received at least one androgen receptor pathway inhibitor, such as enzalutamide or abiraterone. These are the standard hormone therapy drugs used in mCRPC.

Prior taxane chemotherapy. You must have received docetaxel - and in some cases cabazitaxel as well. Having completed at least one course of taxane-based chemotherapy is a formal requirement in the approved indication for most countries.

Adequate organ function. Your kidneys, liver, and bone marrow all need to be functioning within acceptable ranges. Blood tests covering kidney function, liver enzymes, and blood cell counts will be reviewed carefully before each cycle. For a full breakdown of what your team will check, our guide on pre-therapy blood tests and scans for Lu-177 PSMA eligibility covers each test in clear language.

Performance status. You need to be well enough to travel to a nuclear medicine center, sit through an infusion, and recover between cycles. Most centers require an ECOG performance status of 0 to 2, meaning you are able to care for yourself and are up and about for more than half of your waking hours.

Does the Order of Prior Treatments Matter?

Yes, and no. Your care team needs to confirm that you have had both an ARPI and a taxane - but the order in which you received them does not generally disqualify you.

If you received an ARPI first and then docetaxel, and both have since stopped working, you fit within the VISION trial population and the approved indication for this therapy.

If you received docetaxel first and then an ARPI - a common sequence in many countries - the same logic applies. You have had both classes of drug. The approved indication covers you.

If you received docetaxel but have not yet tried an ARPI, the situation is more complex. Most treatment guidelines recommend that all patients with mCRPC receive an ARPI at some point. Your oncologist may advise completing that step before pursuing Lu-177 PSMA therapy, or they may weigh other factors specific to your case, such as how quickly the cancer is growing or your tolerance for further hormone therapy.

Researchers are also exploring whether Lu-177 PSMA can be used earlier in the disease course - before chemotherapy, or right after first ARPI failure. Some clinical trials are examining this. For a detailed look at how Lu-177 PSMA fits into the decision when hormone therapy first fails, see our article on hormone-resistant prostate cancer and weighing Lu-177 PSMA against standard options.

Who May Not Be a Good Candidate After Chemotherapy?

Not everyone will qualify for Lu-177 PSMA therapy even after docetaxel. Your team will look for situations where the treatment may not be safe or work well:

• PSMA-negative or very low PSMA expression on PET scan - if the cancer does not carry enough PSMA, the therapy has no target to bind to
• Significant kidney disease - lutetium-177 clears primarily through the kidneys, so poor kidney function raises the risk of further kidney damage
• Very low blood counts - the radiation can reduce bone marrow activity further, so significant pre-existing anemia, low platelet count, or low white blood cell count may be disqualifying or may require dose adjustments
• Poor performance status - if basic daily activities require full assistance, most centers will need to weigh the risks carefully before proceeding
• Rapidly progressive, high-volume disease - in some cases, a very fast-growing cancer may limit how much benefit a slower-acting radioligand therapy can provide

Being told you do not meet the criteria at one center is not always the final word. Centers differ in how strictly they apply eligibility thresholds, and a second opinion from a nuclear medicine or theranostics specialist can sometimes reveal options that were not fully explored. To understand which baseline factors your team will weigh, our article on baseline factors that predict response to Lu-177 PSMA therapy in mCRPC covers the evidence in detail.

What Can You Realistically Expect from Lu-177 PSMA After Docetaxel?

Lutetium Lu-177 vipivotide tetraxetan is typically given as a series of up to six infusion cycles, spaced about six weeks apart. Each infusion takes place in a nuclear medicine facility and lasts a few hours. Radiation-safety precautions apply for a short period after each infusion - usually one to two weeks - to limit exposure to family members and others around you.

Most patients and clinicians describe side effects as more manageable than chemotherapy for people in the VISION trial. The most common ones include dry mouth (caused by PSMA expression in the salivary glands, which absorb some radiation), fatigue, mild nausea, and temporary reductions in blood cell counts. Serious side effects - including kidney toxicity or significant bone marrow suppression - occur in a smaller proportion of patients and are monitored with blood tests before and between cycles.

Response is typically tracked by PSA levels checked every few weeks and imaging at regular intervals. Some men see a PSA decline within the first one or two cycles. Others see disease stabilization rather than a sharp drop - and stabilization is considered a benefit in slowly progressing disease. Individual results vary and cannot be predicted for any one person.

How Do You Access Lu-177 PSMA Therapy After Chemotherapy?

In the United States, the United Kingdom, Australia, and parts of Europe, lutetium Lu-177 vipivotide tetraxetan is approved and available at specialist cancer centers. However, waiting times, capacity limits, and treatment cost can still be barriers. In some countries it remains unavailable or accessible only through clinical trials.

In India, Lu-177 PSMA therapy is available at several established nuclear medicine and cancer centers. The cost per cycle is much lower than in the US or UK, making India a practical destination for international patients seeking this treatment after chemotherapy progression. For specific costs, see our article on Lu-177 PSMA therapy cost in India versus the US.

Many international patients from the GCC region, Africa, and South Asia travel to India for PSMA therapy after docetaxel has stopped working at home. The process typically starts with a telemedicine consultation and a review of your existing PSMA PET scan to confirm eligibility before you travel for treatment.

If you would like a clinical team to review your case - including your PSMA PET scan results, prior treatment history, and current blood tests - you can request an eligibility review through HealthUnwired. If Lu-177 PSMA therapy turns out not to be the right fit for your situation, the same team can discuss other options as part of a broader second opinion on your treatment plan.

When to Talk to Your Doctor

Talk to your oncologist or seek a specialist review if your latest scan or PSA results show that docetaxel is no longer controlling your cancer. Ask specifically whether you have had a PSMA PET scan - and if not, whether one is warranted. Ask your care team whether you meet the basic eligibility criteria for Lu-177 PSMA therapy and whether any additional steps, such as completing ARPI treatment, are recommended before pursuing radioligand therapy.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.